Medicare Lab Fee Updates Provide Boost for CareDx and BillionToOne

Key Facts

1CMS aligned 2027 clinical lab fees with private payors to achieve $1 billion in savings.

2Both BillionToOne and CareDx received positive rate updates for their tests under the new CMS changes.

In a move reflecting the ongoing restructuring of U.S. healthcare spending, the Centers for Medicare & Medicaid Services (CMS) released updated clinical lab fee schedules for 2027. According to reports, CMS aligned these fees with private payor rates to achieve approximately $1 billion in budgetary savings. Within this regulatory shift, both BillionToOne and CareDx received favorable rate updates for their specific diagnostic tests, providing a potential revenue tailwind for both companies.

This regulatory context highlights the divergence between broader sector cuts and specific reimbursement wins for specialized testing providers. Per market data, BillionToOne (BLLN) closed at $116.07 on September 22, 2026, while CareDx (CDNA) stood at $56.49 as of the same close. These price levels reflect the market's digestion of the new CMS fee structure, which favors the proprietary testing models utilized by these mid-cap healthcare entities.

Traders should watch for further clarification on reimbursement volumes as the 2027 implementation nears. At the close on September 22, 2026, BLLN maintained a position near its daily high of $118.72, while CDNA showed stability after hitting a day high of $56.85. With no major healthcare-specific catalysts in the immediate economic calendar, the long-term impact of these CMS rate adjustments remains the primary focus for institutional positioning in these instruments.